Background
==========

As the most prevalent cardiac arrhythmia in the general population, atrial fibrillation (AF) is associated with a high risk of developing morbidities, such as thromboembolism, stroke and neurologic injury, major and minor organ injury or failure, and hospital re-admissions resulting in significantly increased health care costs \[[@b1-medscimonitbasicres-23-58]--[@b3-medscimonitbasicres-23-58]\]. Moreover, this situation might even exacerbate, since the number of AF patients is expected to double by 2050 \[[@b3-medscimonitbasicres-23-58]\].

The pathophysiological mechanism of increased prothrombotic tendency in patients with AF is highly intricate and multifactorial \[[@b4-medscimonitbasicres-23-58]\]. The association of increased platelet activity with atherosclerotic disease has been well documented \[[@b5-medscimonitbasicres-23-58]\]. Activated platelets have numerous vasoactive and prothrombotic factors \[[@b5-medscimonitbasicres-23-58],[@b6-medscimonitbasicres-23-58]\]. Mean platelet volume (MPV) is a marker of platelet activation and function reflecting platelet size and changes either in terms of platelet stimulation or the rate of platelet production \[[@b6-medscimonitbasicres-23-58]\]. Virchow's triad on prothrombotic state including arterial stasis, vessel wall abnormalities, and coagulant alternations in the hemostatic balance may play a major role in the development of supraventricular arrhythmia \[[@b7-medscimonitbasicres-23-58]\]. Platelets represent an important part of hemostatic balance and can directly affect prothrombotic state.

Various studies have reported the association of hemostatic markers with the occurrence of AF. However, so far the data from the studies have been largely inconclusive. This systematic review with meta-analysis aimed to determine the strength of evidence for evaluating the association of platelet cellular and functional characteristics including platelet count, MPV, platelet distribution width (PDW), platelet factor 4, beta thromboglobulin (BTG), and p-selectin with the occurrence of AF and consequent stroke.

Material and Methods
====================

Literature search
-----------------

A comprehensive literature search was conducted in electronic scientific databases (Medline/PubMed, Web of Science, Embase, and Google Scholar) from their inception through August 10, 2016 to identify relevant studies on the association of platelet cellular and functional characteristics with the occurrence of AF and consequent stroke. Predefined search terms were as follows: "platelet count", "mean platelet volume", "platelet distribution width", "platelet factor 4", "beta thromboglobulin", "P-selectin", and "atrial fibrillation" or "supraventricular arrhythmia". No restrictions were applied regarding language, time of publication, or sample size of studies. To assess additional studies not indexed in common databases, all retrieved references of the enrolled studies, recent published review articles, and meta-analyses were also checked.

Study selection
---------------

Studies were included in the analysis when they met the following criteria: 1) human subjects; 2) cohort or case-control studies; 3) the study investigated the comparison between AF-cases and non-AF-population in terms of platelet biomarkers; 4) the study compared patients with and without stroke focusing on biomarkers. Abstracts without peer-review or from congress presentations only, as well as gray literature were not included.

Data extraction and outcome measures
------------------------------------

Three investigators (S.A-H-S, S-J.M, and A.S) independently extracted the data. Discrepancies were resolved by a consensus standardized abstraction checklist used for recording data in each included study. Disagreements were discussed and resolved by senior authors (A.F-P, A.W, G.B.Z, and H.C). Author's name, year of publication, country, design of study, sample size, mean age, gender, coexistent cardiovascular diseases and risk factors, such as diabetes mellitus, hypertension and history of myocardial infarction, percentage of used anti-coagulants, type of AF, and details of platelet markers were extracted. For exploration of heterogeneity among trials, subgroup analyses of disparities in the patients' characteristics were performed for 1) the era of publication (before 2000 versus after 2000); 2) geographical area (Asia, Europe, Africa, North-America, South-America, and Oceania); 3) study design (case-control versus cohort); 4) size of patient cohort (≤300 versus \>300); 5) mean age (≤60 years versus \>60 years); 6) percentage of male patients (≤70% versus \>70%); 7) presence of diabetes (≤30% versus \>30%); 8) presence of hypertension (≤70% versus \>70%); 9) history of cigarette smoking (≤0% versus \>30%); 10) presence of myocardial infarction (≤20% versus \>20%); 11) use of cardiovascular drugs, such as diuretics, angiotensin converting enzyme inhibitors, statins and beta-blockers (for each: ≤70% versus \>70%); 12) AF-classification (chronic versus non-chronic; duration of AF ≥6 months and ≥1 attempt of electrical cardioversion to restore normal sinus rhythm were considered chronic AF and patients with duration of AF ≤6 months were considered non-chronic AF); 13) type of AF \[paroxysmal (spontaneous termination of the arrhythmia within 7 days of its onset), persistent (sustained arrhythmia beyond 7 days), permanent (efforts to restore normal sinus rhythm have either failed or been forgone)\]; and 12) anticoagulation (code-1: patients did not receive anticoagulants in both groups, code-2: all participants received anticoagulants in both groups, code-3: range of percentages between both groups \>5 0%, code-4: range of percentages between both groups \<50%, code-5: no information available about anticoagulation in both groups, and code-6: anticoagulation information not available for one group only).

Homogenization of extracted data
--------------------------------

Continuous data were expressed as mean ± standard deviation (SD). For studies reporting interquartile ranges, the mean was estimated according to \[minimum+maximum+2(median)\]/4 and SD was calculated based on (maximum--minimum)/4 for groups with sample sizes of n ≤70 and (maximum--minimum)/6 for sample sizes of \>70 \[[@b8-medscimonitbasicres-23-58]\].

Quality assessment and statistical analysis
-------------------------------------------

The Newcastle-Ottawa scale was independently used by two investigators (S.A-H-S and M.G) to assess the quality of studies \[[@b9-medscimonitbasicres-23-58]\]. Total scores ranged from 0 (worst quality) to 9 (best quality) for case-control or cohort studies. Data were analyzed by STATA 11.0 using METAN and METABIAS modules. For non-categorical data, pooled effect size measured was weighted mean difference (WMD) with 95% CI. A *p* value \<0.1 for Q test or I^2^ \>50% showed significant heterogeneity among the studies. Heterogeneity among trials was examined by applying a random effect model when indicated. Publication bias was assessed using the Begg tests. A *p* value \<0.05 was considered statistically significant.

Results
=======

Literature search strategy and included studies
-----------------------------------------------

A total of 1,676 studies were retrieved from the literature search and screened databases, of which 1,005 studies (59.9%) were excluded after meticulous evaluation during the first review due to either unnecessary information (n=710), inadequate report of endpoints of interest (*n*=265) or report of non-matched data based on mean ±SD or median \[minimum-maximum\] (*n*=30). In total, 671 potentially relevant full-text articles were reviewed, and finally 73 studies were analyzed in the meta-analysis ([Supplementary Table 1](#s9-medscimonitbasicres-23-58){ref-type="supplementary-material"}).

Association of platelet characteristics with AF
-----------------------------------------------

### Platelet count

A total of 6,255 cases were selected from 45 studies, of which 2,964 were allocated to the AF group and 3,291 to the SR group. Patient populations in the selected studies ranged from 27 to 621 patients. Mean platelet count was 237.3×10^9^/L in AF group and 240.04×10^9^/L in SR ([Tables 1](#t1-medscimonitbasicres-23-58){ref-type="table"}, [2](#t2-medscimonitbasicres-23-58){ref-type="table"}). Using a random effect model, pooled assessment effect analysis indicated that the mean platelet count was significantly lower in patients with AF than in patients with SR with WMD of −26.93 (95% CI: −28.35 to −25.51; *p*\<0.001, [Figure 1](#f1-medscimonitbasicres-23-58){ref-type="fig"}). Significant heterogeneity was observed among the studies (I^2^=93.5%; heterogeneity *p*\<0.001).

### MPV

A total of 3,609 cases were included from 19 studies, of which 1,646 were allocated to the AF group and 1,963 to the SR. Patient populations of the included studies ranged from 57 to 621 patients. Mean level of MPV was 9.22 FL in the AF group and 8.40 FL in the SR group ([Tables 1](#t1-medscimonitbasicres-23-58){ref-type="table"}, [2](#t2-medscimonitbasicres-23-58){ref-type="table"}). Pooled analysis revealed that MPV level was significantly higher in patients with AF compared to those with SR with WMD of 0.61 (95% CI: 0.56 to 0.65; *p*\<0.001, [Figure 2](#f2-medscimonitbasicres-23-58){ref-type="fig"}) using a random effect model. There was a significant heterogeneity among the studies (I^2^=94.3%; heterogeneity *p*\<0.001).

### PDW

A total of 1,117 cases were included from three studies, of which 290 were allocated to the AF group and 827 to the SR group. Using a random effect model, pooled analysis revealed that PDW was statistically lower in the AF group than in the SR group with WMD of −0.22 (95% CI: −0.37 to −0.08; *p*=0.002, [Supplementary Figure 1](#s1-medscimonitbasicres-23-58){ref-type="supplementary-material"}). There was significant heterogeneity among the studies (I^2^=87.4%; heterogeneity *p*\<0.001)

### BTG

A total of 1,781 patients were included from 22 studies, of whom 1,043 were allocated to the AF group and 738 to the SR. Mean level of BTG was 83.62 ng/mL in patients with AF and 58.72 ng/mL in those with SR ([Tables 1](#t1-medscimonitbasicres-23-58){ref-type="table"}, [2](#t2-medscimonitbasicres-23-58){ref-type="table"}). Pooled analysis revealed that the mean level of BTG was significantly higher in AF patients compared to those with SR with WMD of 24.69 (95% CI: 24.07 to 25.32; *p*\<0.001, [Figure 3](#f3-medscimonitbasicres-23-58){ref-type="fig"}) with considerable heterogeneity among the studies (I^2^=97.6%; heterogeneity *p*\<0.001).

### PF4

A total of 1,220 cases were selected from 16 studies, of which 651 were allocated to the AF group and 569 to the SR group. Mean levels of PF4 were 41.43 ng/mL in the AF group and 24.78 ng/mL in the SR group ([Tables 1](#t1-medscimonitbasicres-23-58){ref-type="table"}, [2](#t2-medscimonitbasicres-23-58){ref-type="table"}). Pooled analysis showed that the level of PF4 was remarkably higher in patients suffering AF compared to controls with WMD of 4.59 ng/mL (95% CI: 4.33 to 4.86; *p*\<0.001, [Figure 4](#f4-medscimonitbasicres-23-58){ref-type="fig"}) using a random effect model. There was significant heterogeneity among the studies (I^2^=99.6%; heterogeneity *p*\<0.001).

### P-selectin

A total of 2,725 cases were included from 24 studies, of which 1,469 were allocated to the AF group and 1,256 to the SR. Mean level of P-selectin was 69.52 ng/mL in the AF group and 51.51 ng/mL in the SR group ([Tables 1](#t1-medscimonitbasicres-23-58){ref-type="table"}, [2](#t2-medscimonitbasicres-23-58){ref-type="table"}). Using a random effect model, pooled analysis showed that the level of P-selectin was significantly higher in the AF group compared to the SR group with WMD of 4.90 ng/mL (95% CI: 4.36 to 5.45; *p*\<0.001, [Figure 5](#f5-medscimonitbasicres-23-58){ref-type="fig"}). Significant heterogeneity was observed among the studies (I^2^=98.6%; heterogeneity *p*\<0.001).

Association of platelet characteristics with the incidence of stroke in patients with AF
----------------------------------------------------------------------------------------

Five studies examined the association of platelet markers with stroke ([Table 3](#t3-medscimonitbasicres-23-58){ref-type="table"}). Platelet count and MPV were investigated in at least two studies which were included in the meta-analysis ([Table 3](#t3-medscimonitbasicres-23-58){ref-type="table"}). According to pooled assessment analysis, the level of MPV (number of studies=2, WMD of 0.97, 95% CI: 0.70 to 1.24; *p*\<0.001 and I^2^=95%%; heterogeneity *p*\<0.001, [Supplementary Figure 2](#s2-medscimonitbasicres-23-58){ref-type="supplementary-material"}) was significantly higher in patients with stoke compared to those without major cerebrovascular events. Pooled analysis showed that platelet count (number of studies=4, WMD of 7.23, 95% CI: −4.96 to 19.42; *p*=0.245 and I^2^=35.2%%; heterogeneity *p*=0.21, [Supplementary Figure 3](#s3-medscimonitbasicres-23-58){ref-type="supplementary-material"}) was not significantly different in patients with or without stroke.

Publication bias and subgroup analysis
--------------------------------------

Begg tests suggested that there might be publication bias for studies examining the levels of MPV and BTG ([Supplementary Figures 4](#s4-medscimonitbasicres-23-58){ref-type="supplementary-material"}--[8](#s8-medscimonitbasicres-23-58){ref-type="supplementary-material"}). Details of subgroup analysis are reported in [Supplementary Tables 2](#s10-medscimonitbasicres-23-58){ref-type="supplementary-material"} and [3](#s11-medscimonitbasicres-23-58){ref-type="supplementary-material"}.

Discussion
==========

The incidence of cardiovascular diseases has been dramatically increasing in developed and developing countries in recent decades \[[@b1-medscimonitbasicres-23-58]\]. AF represents one of the most critical and prevalent cardiac arrhythmias precipitating morbidity and mortality in short- and long-term periods of time and adversely affecting patient's quality of life \[[@b1-medscimonitbasicres-23-58],[@b2-medscimonitbasicres-23-58]\]. Despite the wide range of investigations on diagnosis and treatment of AF conducted and published in recent years, the pathophysiology of this multifactorial disease is not completely understood \[[@b2-medscimonitbasicres-23-58]\]. Due to a number of complex mechanisms that are involved in the development of AF the current controversies regarding diagnosis and treatment of AF seem to be justifiable \[[@b2-medscimonitbasicres-23-58],[@b3-medscimonitbasicres-23-58]\]. Among other things the mechanism of oxidation and release of free radical oxygen has been defined as one of the main precipitating mechanisms in development of AF \[[@b2-medscimonitbasicres-23-58]\]. Also, the Virchow's triad, which plays a critical role in predicting AF and includes arterial stasis, vessel wall abnormalities, and coagulant alternations in the hemostatic balance, indicates that prothrombotic state is another important pathophysiological mechanism of AF. However, the exact mechanism involving prothrombotic state in AF is ambiguous \[[@b6-medscimonitbasicres-23-58],[@b7-medscimonitbasicres-23-58]\]. Nevertheless, it is known that platelets are involved in both thrombosis and inflammation becoming a key factor in pathogenesis of cardiovascular diseases \[[@b6-medscimonitbasicres-23-58]\]. In the present study, we attempted conducting a meticulous and multilateral investigation on platelets cellular and functional characteristics in patients with AF compared to patients with sinus rhythm. Our findings revealed that from statistical and clinical points of view, AF was significantly associated with reduced platelet count. However, an undeniable fact is that a considerable heterogeneity among the studies was present in this analysis. A subgroup analysis revealed that the type of AF (chronic or non-chronic) could probably be a factor of heterogeneity: there was an inverse relationship between the occurrence of AF and platelet count in non-chronic AF, while such an association was not observed in patients with chronic AF. On the other hand, reduced platelet count was not observed in paroxysmal and permanent AF, while this relationship only existed in persistent AF. In general, it can be concluded that the type of AF is one of the heterogeneity factors in platelet count analysis. Barura et al. reported that exposure to cigarette smoking could change the hemostatic process through multiple mechanisms including alteration of the function of endothelial cells, platelets, and coagulation factors \[[@b10-medscimonitbasicres-23-58]\]. However, our subgroup analysis demonstrated that platelet count was not significantly reduced in cigarette smokers with AF compared to smokers with SR, while lower platelet count was observed in non-smokers with AF compared to smokers with SR. This can be explained by the fact that cigarette smoking can disturb the actual platelet count via increasing aggregation and adhesion of the platelets \[[@b10-medscimonitbasicres-23-58]\]. In fact, we believe that the occurrence of AF is strongly associated with reduced platelet count while the type of AF, cigarette smoking, and the geographical area of the studies represent factors of heterogeneity.

MPV is also an important biomarker of platelet activity. Large platelets secrete many critical mediators of coagulation, inflammation, thrombosis, and atherosclerosis. A close relationship has been found between MPV and cardiovascular risk factors, such as diabetes mellitus, hypertension, and hypercholesterolemia \[[@b11-medscimonitbasicres-23-58],[@b12-medscimonitbasicres-23-58]\]. The results of this study revealed that the average MPV was significantly higher in AF patients than in SR patients, thus implying the direct relationship between MPV and the risk of AF. According to our subgroup analysis, study sample size and diabetes mellitus could probably result in heterogeneity. Our findings also showed that levels of the platelet markers were notably higher in both chronic and non-chronic AF patients compared to the SR group. Interestingly, Sansanayudh et al. recently found an association between elevated MPV and CAD. Patients with CAD and slow coronary blood flow showed larger MPV compared to controls \[[@b13-medscimonitbasicres-23-58]\]. The mean difference in MPV in patients with an acute coronary event was higher than those with stable coronary disease \[[@b13-medscimonitbasicres-23-58]\]. They suggested that MPV might be used for risk stratification or to add diagnostic accuracy to the traditional risk stratification markers in patients with CAD \[[@b13-medscimonitbasicres-23-58]\].

PWD is a platelet biomarker and predictive factor in cardiovascular diseases. Varastehravan et al. indicated that PDW in patients with ST-segment elevation myocardial infarction could be used for prediction of ST-segment resolution and clinical outcomes \[[@b14-medscimonitbasicres-23-58]\]. According to the results of the present study, PDW was greater in patients with AF than those with SR and thus had a direct relationship to the risk of AF. However, due to the limited number of studies on PDW no subgroup analysis could be performed to examine heterogeneity factors. Nevertheless, our evidence shows that AF might be associated with both larger volume of platelets as well as distribution width.

Platelet activation is demonstrated by the release of platelet granules and their components into the circulation. BTG and platelet factor 4 (PF4) represent specific platelet proteins of alpha-granules, which can be secreted into surrounding medium during cell activation \[[@b15-medscimonitbasicres-23-58],[@b16-medscimonitbasicres-23-58]\]. Based on the results of this study, increased levels of BTG might be also directly related to the risk of AF. Our subgroup analysis revealed the type of AF (chronic or non-chronic), history of CS, and gender as factors of heterogeneity. The present study also indicated that the level of PF4 was remarkably higher in AF patients compared to those with SR, while the level of BTG and PF4 were significantly increased compared to SR patients in both chronic and non-chronic AF as well as paroxysmal and permanent AF. Therefore, it can be suggested that platelet activity and release of specific proteins from their granules may also play a vital role in pathophysiology of AF.

P-selectin, an integral membrane glycoprotein of platelets and endothelial cells, is involved in the onset of atherosclerosis and cardiovascular diseases \[[@b17-medscimonitbasicres-23-58]\]. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells, which line the inner surface of blood vessels, and activated platelets. In unactivated endothelial cells, it is stored in α-granules \[[@b17-medscimonitbasicres-23-58]\]. The present study revealed that P-selectin marker was notably higher in AF patients compared to SR group. The subgroup analysis proposed the type of studies and the type of AF as factors of heterogeneity. In brief, cohort studies did not show any relationship between the level of P-selectin and occurrence of AF, whereas case-control studies strongly confirmed this relationship. It is necessary to mention that the number of cohort studies was remarkably less than case-control studies. Increased level of P-selectin was observed in both chronic and non-chronic AF in our meta-analysis. On the other hand, this association was found in persistent and permanent AF but not in paroxysmal AF. Overall, taking into account the evidence from the present study, platelet count and other biomarkers may considerably influence the development of AF underlying the role of platelets in pathophysiology of AF as well as the predictive function of platelet factors.

The results of our study showed that the level of MPV was obviously higher in AF patients with stroke as compared to AF patients without cerebrovascular events. However, we found no association between platelet count and the occurrence of stroke.

There is a hypothesis that cardiac risk factors might also affect the occurrence of AF. Feng et al. proposed a hypothesis that the relationship between hemostatic markers and AF became insignificant after stratifying based on cardiovascular disease status \[[@b18-medscimonitbasicres-23-58]\]. Our results showed that cardiac risk factors including diabetes, hypertension, and history of MI were not recognized as heterogeneity factors. However, it should be mentioned that an important cardiac risk factor affecting our results was cigarette smoking.

Lip et al. argued that using anticoagulants could reduce the level of hemostatic factors in AF patients, and consequently, differences in receiving anticoagulants in various studies could be considered as a factor of heterogeneity \[[@b19-medscimonitbasicres-23-58]\]. According to the results of our subgroup analyses of platelet count and level of MPV and PF4, differences in using anticoagulants could possibly play a considerable role in the occurrence of heterogeneity. It should also be noted that in our meta-analysis on non-experimental studies more heterogeneity was found which may be explained by the following reasons: 1) biases are less controlled, 2) more confounding factors, and 3) differences in defining outcomes. As a result, performing analysis on non-experimental studies, finding associations, effect size, and estimating heterogeneity as well as appropriate method for finding the factors of heterogeneity should be the aim of such meta-analyses.

Conclusions
===========

In summary, considering the results of this study, we strongly state that platelets play a critical and precipitating role in the occurrence of AF as the volume and distribution width of platelets as well as the factors of platelet activity appeared to be significantly higher in AF patients compared to SR patients. On the other hand, AF was associated with lower platelet count. Therefore, emphasizing the potential predictive role of platelet factors in the occurrence of AF, we strongly recommend adding cellular and functional characteristics of platelets to the diagnostic criteria of AF in the future.

Supplementary Files
===================

###### 

Forest plot of weighted mean difference (WMD) for association between level of platelet distribution width and occurrence of AF.

###### 

Forest plot of weighted mean difference (WMD) for association between level of mean platelet volume and occurrence of stroke.

###### 

Forest plot of weighted mean difference (WMD) for association between level of platelet count and occurrence of stroke.

###### 

Funnel plot for publication bias of studies investigating of platelet count.

###### 

Funnel plot for publication bias of studies investigating of mean platelet volume.

###### 

Funnel plot for publication bias of studies investigating of beta thromboglobulin.

###### 

Funnel plot for publication bias of studies investigating of platelet factor-4.

###### 

Funnel plot for publication bias of studies investigating of P-selectin.

###### 

Included and excluded studies.

  Clinical outcomes and biomarkers   Studies were identified and screened \[n\]   Studies were excluded according to title, abstract or full text \[n\]   Studies were included \[n\]
  ---------------------------------- -------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------
  Platelet count                     285                                          252                                                                     33 approved articles with totally 45 enrolled data for meta-analysis
  Mean platelet volume               140                                          125                                                                     15 approved articles with totally 19 enrolled data for meta-analysis
  Platelet distribution width        11                                           9                                                                       2 approved articles with totally 3 enrolled data for meta-analysis
  Beta thromboglobulin               66                                           51                                                                      15 approved articles with totally 22 enrolled data for meta-analysis
  Platelet factor 4                  54                                           44                                                                      10 approved articles with totally 16 enrolled data for meta-analysis
  P-selectin                         115                                          97                                                                      18 approved articles with totally 24 enrolled data for meta-analysis

###### 

Extra details of characteristics of each study for exploration of heterogeneity factors.

  First Author                                                                     Geographic Area   Total N   Total age   Total male   Total DM   Total HTN   Total MI   Total Diuretic   Total ACEI   Total. Statin   Total BB   AC-code   Chronic or not   CS
  -------------------------------------------------------------------------------- ----------------- --------- ----------- ------------ ---------- ----------- ---------- ---------------- ------------ --------------- ---------- --------- ---------------- -------
  Karatas \[[@b20-medscimonitbasicres-23-58]\]                                     European          621       61.05       72.5         23         45.5        ND         ND               ND           0               ND         2         Non-chronic      64
  Drabik \[[@b21-medscimonitbasicres-23-58]\]                                      European          97        60.1        64.95        20         48.85       17.3       ND               52.25        53.15           60.6       4         Non-chronic      22.85
  Drabik \[[@b21-medscimonitbasicres-23-58]\]                                      European          91        60          55.15        16.4       46.05       26.2       ND               54.05        47.45           57.25      4         Non-chronic      20
  Idriss \[[@b22-medscimonitbasicres-23-58]\]                                      Africa            41        31.75       49.25        0          0           ND         ND               ND           ND              11.9       4         ND               34.5
  Akdag \[[@b23-medscimonitbasicres-23-58]\]                                       European          148       64.05       60           16.5       22          ND         ND               ND           ND              ND         6         ND               23.5
  Akyuz \[[@b24-medscimonitbasicres-23-58]\]                                       European          90        62.25       72.25        29         42.5        ND         14.5             20.75        32.5            23         4         ND               34.25
  Chavaria \[[@b25-medscimonitbasicres-23-58]\]                                    North American    290       65.65       74.5         29.05      65.65       4.5        ND               ND           ND              ND         5         ND               55.05
  Erdogan \[[@b26-medscimonitbasicres-23-58]\]                                     European          67        69.55       49.25        10         65          ND         18               53.5         10              43.3       3         chronic          6
  Xu (without comorbidities) \[[@b27-medscimonitbasicres-23-58]\]                  Asian             115       66.05       50.45        37.4       53.1        ND         ND               42.6         29.55           43.55      4         chronic          38.25
  Xu (with comorbidities) \[[@b27-medscimonitbasicres-23-58]\]                     Asian             115       67.975      51.3         36.5       57.5        ND         ND               40.8         26.05           40.95      4         chronic          31.25
  Acet (PAF) \[[@b28-medscimonitbasicres-23-58]\]                                  European          134       62.05       44           16.5       18          ND         ND               ND           ND              ND         5         Non-chronic      21.5
  Acet (persistent and permanent) \[[@b28-medscimonitbasicres-23-58]\]             European          126       62.85       43.5         21.5       24          ND         ND               ND           ND              ND         5         ND               28.5
  Arik (with INR 2--3) \[[@b29-medscimonitbasicres-23-58]\]                        European          248       69.65       40.7         6.05       68.95       ND         27               59.25        ND              59.7       5         chronic          13.7
  Arik (with abnormal INR) \[[@b29-medscimonitbasicres-23-58]\]                    European          248       69.45       37.9         6.85       65.35       ND         24.2             55.65        ND              61.3       5         chronic          12.1
  Distelmaier \[[@b30-medscimonitbasicres-23-58]\]                                 North American    198       73.5        61           24         60.5        25         ND               ND           ND              ND         5         Non-chronic      ND
  Gungor \[[@b31-medscimonitbasicres-23-58]\]                                      European          177       47.2        57.8         3.3        14.75       ND         ND               ND           ND              10.6       3         ND               23.15
  Sonmez \[[@b32-medscimonitbasicres-23-58]\]                                      European          85        70          36.95        10.6       63.25       ND         14.1             47.15        15.4            35.55      4         Non-chronic      ND
  Ulu \[[@b33-medscimonitbasicres-23-58]\]                                         European          57        ND          ND           ND         ND          ND         ND               ND           ND              ND         5         ND               ND
  Turgut \[[@b34-medscimonitbasicres-23-58]\]                                      European          162       63          52           100        65.5        ND         6.5              23.5         18              16.5       4         chronic          41.5
  Jaremo (healthy control) \[[@b35-medscimonitbasicres-23-58]\]                    European          82        67.5        66.7         ND         ND          ND         ND               ND           ND              ND         4         ND               2.55
  jaremo (disease control) \[[@b35-medscimonitbasicres-23-58]\]                    European          130       71.5        68.1         12.75      43.75       9.1        28.65            26.25        25.05           55.9       4         ND               9.45
  Berge \[[@b36-medscimonitbasicres-23-58]\]                                       European          189       75          71           8          48          ND         19               21           34.5            28         4         ND               ND
  Ertas (without stroke) \[[@b37-medscimonitbasicres-23-58]\]                      European          111       53.5        51           ND         ND          ND         ND               ND           ND              ND         6         ND               2
  Ertas (with stroke) \[[@b37-medscimonitbasicres-23-58]\]                         European          63        54.5        47           ND         ND          ND         ND               ND           ND              ND         6         ND               5
  Sahin \[[@b38-medscimonitbasicres-23-58]\]                                       European          144       64.9        49.75        100        66.5        ND         ND               ND           ND              ND         5         Non-chronic      44.5
  Tekin \[[@b39-medscimonitbasicres-23-58]\]                                       European          219       73.5        35.5         13.5       68.5        ND         ND               ND           ND              ND         5         chronic          19
  Turfan (without CVA) \[[@b40-medscimonitbasicres-23-58]\]                        European          135       59.5        54.55        ND         ND          ND         ND               ND           ND              ND         4         ND               55.5
  Turfan (with CVA) \[[@b40-medscimonitbasicres-23-58]\]                           European          121       62.5        52.05        ND         ND          ND         ND               ND           ND              ND         4         ND               50.6
  Feng \[[@b41-medscimonitbasicres-23-58]\]                                        Asian             374       65.8        61.75        17.65      53.2        ND         23               41.95        44.85           42.5       4         ND               25.65
  Acevedo \[[@b42-medscimonitbasicres-23-58]\]                                     South American    150       ND          ND           ND         ND          ND         ND               ND           ND              ND         1         Non-chronic      ND
  Hayashi \[[@b43-medscimonitbasicres-23-58]\]                                     Asian             27        57.95       92.5         14.5       48.5        ND         ND               40.5         26              ND         2         Non-chronic      ND
  Hayashi \[[@b43-medscimonitbasicres-23-58]\]                                     Asian             27        61.45       92.5         11.05      52          ND         ND               37           26              ND         2         chronic          ND
  Fu \[[@b44-medscimonitbasicres-23-58]\]                                          Asian             169       54.45       63.5         ND         ND          ND         ND               ND           12.9            6.1        4         ND               42.45
  Hou (disease control) \[[@b45-medscimonitbasicres-23-58]\]                       Asian             52        64.85       57.6         ND         ND          ND         ND               40.3         ND              11.45      4         Non-chronic      26.9
  Hou (healthy control) \[[@b45-medscimonitbasicres-23-58]\]                       Asian             52        65.3        57.6         ND         ND          ND         ND               21.15        ND              7.65       4         Non-chronic      26.9
  Alberti \[[@b46-medscimonitbasicres-23-58]\]                                     European          51        64.45       58.8         ND         ND          ND         ND               ND           ND              ND         1         Non-chronic      ND
  Choudhury (disease control) \[[@b47-medscimonitbasicres-23-58]\]                 European          192       63.31       74           10.5       66.4        ND         33.15            55.7         46.5            43.7       4         ND               ND
  Choudhury (healthy control) \[[@b47-medscimonitbasicres-23-58]\]                 European          186       62.305      72           4.1        31.8        ND         17.75            26.85        14.45           21.9       4         ND               ND
  Colkesen \[[@b48-medscimonitbasicres-23-58]\]                                    European          190       54          38           18.5       41.5        ND         ND               ND           28              ND         4         Non-chronic      ND
  Blann \[[@b49-medscimonitbasicres-23-58]\]                                       European          82        64.5        62.75        ND         27          ND         16.5             19           ND              18.5       3         ND               12.6
  Topaloglu (disease control) \[[@b50-medscimonitbasicres-23-58]\]                 European          46        34.5        ND           ND         ND          ND         ND               ND           ND              ND         5         ND               ND
  Topaloglu (healthy control) \[[@b50-medscimonitbasicres-23-58]\]                 European          38        36          ND           ND         ND          ND         ND               ND           ND              ND         5         ND               ND
  Yip \[[@b51-medscimonitbasicres-23-58]\]                                         Asian             82        65.75       63.05        ND         ND          ND         ND               ND           ND              ND         3         chronic          ND
  Heeringa \[[@b52-medscimonitbasicres-23-58]\]                                    European          486       77.5        51           17.5       25          22.5       31.65            ND           ND              16.55      5         ND               20.9
  Inoue (with comorbidities) \[[@b53-medscimonitbasicres-23-58]\]                  Asian             251       ND          ND           ND         ND          ND         ND               ND           ND              ND         5         ND               ND
  Inoue (lone AF) \[[@b53-medscimonitbasicres-23-58]\]                             Asian             106       ND          ND           ND         ND          ND         ND               ND           ND              ND         5         ND               ND
  Conway \[[@b54-medscimonitbasicres-23-58]\]                                      European          147       68          62           7.5        26.5        ND         ND               ND           ND              ND         3         chronic          16
  Conway \[[@b55-medscimonitbasicres-23-58]\]                                      European          74        67.5        70.23        12.95      37          1.85       ND               ND           ND              ND         5         Non-chronic      16.2
  Atalar (paroxysmal AF) \[[@b56-medscimonitbasicres-23-58]\]                      European          37        46          61.8         0          35.9        ND         ND               ND           ND              17.845     1         Non-chronic      ND
  Atalar (permanent AF) \[[@b56-medscimonitbasicres-23-58]\]                       European          47        49          63.8         0          35.9        ND         ND               ND           ND              17.845     1         chronic          ND
  Kamath \[[@b57-medscimonitbasicres-23-58]\]                                      European          62        63.5        51.6         ND         ND          ND         ND               ND           ND              ND         1         Non-chronic      ND
  Kamath \[[@b57-medscimonitbasicres-23-58]\]                                      European          124       66          52.65        ND         ND          ND         ND               ND           ND              ND         1         chronic          ND
  Kamath \[[@b58-medscimonitbasicres-23-58]\]                                      European          58        63          48.235       6.85       24.1        ND         ND               ND           ND              ND         4         Non-chronic      5.15
  Kamath \[[@b58-medscimonitbasicres-23-58]\]                                      European          116       65          52.25        5.15       30.45       ND         ND               ND           ND              ND         4         chronic          5.15
  Kamath \[[@b59-medscimonitbasicres-23-58]\]                                      European          143       70          63.2         5.35       29.565      ND         ND               ND           ND              ND         1         ND               ND
  Kamath \[[@b60-medscimonitbasicres-23-58]\]                                      European          57        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         ND               ND
  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  European          43        64          77.3         2.15       10.85       ND         ND               ND           ND              ND         3         Non-chronic      13.65
  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  European          43        64          77.3         2.15       13          ND         ND               ND           ND              ND         3         Non-chronic      11.52
  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  European          43        65          77.3         6.52       23.9        ND         ND               ND           ND              ND         3         chronic          11.52
  Mondillo \[[@b62-medscimonitbasicres-23-58]\]                                    European          80        66.95       82.85        ND         ND          ND         ND               ND           ND              ND         3         chronic          33.75
  Li-Saw-Hee \[[@b63-medscimonitbasicres-23-58]\]                                  European          112       67          77.5         3.85       12.5        ND         ND               ND           ND              ND         1         ND               13.3
  Li-Saw-Hee \[[@b64-medscimonitbasicres-23-58]\]                                  European          50        59          20           ND         ND          ND         ND               ND           ND              ND         5         chronic          20
  Minamino \[[@b65-medscimonitbasicres-23-58]\]                                    European          56        64          71.4         21.5       25          ND         ND               ND           ND              19.5       4         chronic          37.5
  Minamino \[[@b66-medscimonitbasicres-23-58]\]                                    Asian             90        63          73.3         12.5       23.5        ND         ND               ND           ND              14.5       5         chronic          39
  Kahn \[[@b67-medscimonitbasicres-23-58]\]                                        North American    81        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         ND               ND
  Sohara \[[@b68-medscimonitbasicres-23-58]\]                                      Asian             30        59.05       ND           ND         ND          ND         ND               ND           ND              ND         1         Non-chronic      ND
  Lip GY \[[@b69-medscimonitbasicres-23-58]\]                                      European          77        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         chronic          ND
  Nagao \[[@b70-medscimonitbasicres-23-58]\]                                       Asian             36        79.95       47.05        ND         ND          ND         ND               ND           ND              ND         1         ND               ND
  Sohara \[[@b71-medscimonitbasicres-23-58]\]                                      Asian             28        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         Non-chronic      ND
  Gustafsson (with stroke) \[[@b72-medscimonitbasicres-23-58]\]                    European          60        77          ND           ND         ND          ND         ND               ND           ND              ND         1         ND               ND
  Gustafsson (without stroke) \[[@b72-medscimonitbasicres-23-58]\]                 European          60        77          ND           ND         ND          ND         ND               ND           ND              ND         1         ND               ND
  Yamauchi (without valvular heart disease) \[[@b73-medscimonitbasicres-23-58]\]   Asian             130       41.5        ND           ND         ND          ND         ND               ND           ND              ND         1         ND               ND
  Yamauchi (with valvular heart disease) \[[@b73-medscimonitbasicres-23-58]\]      Asian             83        45.5        ND           ND         ND          ND         ND               ND           ND              ND         1         ND               ND

###### 

Subgroup-analysis

  Subgroup                      Studies (N)                                                    WMD (95% CI)                I-squared and Heterogeneity-p-value and Effect-p-value respectively
  ----------------------------- -------------------------------------------------------------- --------------------------- ---------------------------------------------------------------------
  **Platelet count**                                                                                                       
                                                                                                                           
  Year of publication                                                                                                      
   \>2000                       41                                                             −24.04 (−25.52 to −22.56)   91.1% and 0.001 and 0.001
   ≤2000                        4                                                              −60.67 (−65.22 to −55.62)   92.8% and 0.001 and 0.001
                                                                                                                           
  Geographic area                                                                                                          
   Asian                        7                                                                                          13.8% and 0.324 and 0.284
   European                     35                                                             −3.88 (−10.98 to 3.21)      94% and 0.001 and 0.001
   Africa                       \-                                                             −30.05 (−31.59 to −28.50)   --
   North American               3                                                              --                          0.0% and 0.401 and 0.001
   South American               \-                                                             −12.23 (−16.39 to −8.08)    --
   Australia                    \-                                                                                         --
                                                                                                                           
  Design of study                                                                                                          
   Cohort                       8                                                              −29.32 (−31.25 to −27.40)   91.6% and 0.001 and 0.001
   Case-control                 37                                                             −24.10 (−26.20 to −22.01)   93.8% and 0.001 and 0.001
                                                                                                                           
  Number of population                                                                                                     
   \>300                        2                                                              −6.33 (−19.68 to 7.02)      0.0% and 0.689 and 0.353
   ≤300                         43                                                             −27.16 (−28.59 to −25.74)   93.7% and 0.001 and 0.001
                                                                                                                           
  Mean Age                                                                                                                 
   \>60 years                   34                                                             −27.90 (−29.34 to −26.46)   94.5% and 0.001 and 0.001
   ≤60 years                    7                                                              −0.76 (−9.25 to 7.12)       76.7% and 0.001 and 0.860
                                                                                                                           
  Male                                                                                                                     
   \>70%                        8                                                              −29.82 (−31.76 to −27.88)   85.8% and 0.001 and 0.001
   ≤70%                         31                                                             −16.15 (−18.44 to −13.86)   90.6% and 0.001 and 0.001
                                                                                                                           
  Diabetes mellitus                                                                                                        
   \>30%                        1                                                              21.00 (−4.40 to 46.40)      --
   ≤30%                         28                                                             −22.68 (−24.24 to −21.12)   88.3% and 0.001 and 0.001
                                                                                                                           
  Hypertension                                                                                                             
   \>70%                        --                                                             --                          --
   ≤70%                         29                                                             −22.52 (−24.07 to −20.96)   88.4% and 0.001 and 0.001
                                                                                                                           
  History of MI                                                                                                            
   \>20%                        2                                                              −11.74 (−15.35 to −8.13)    9.7% and 0.293 and 0.001
   ≤20%                         3                                                              −15.44 (−22.10 to −8.77)    31.1% and 0.234 and 0.001
                                                                                                                           
  Medication: Diuretic                                                                                                     
   \>70%                        --                                                             --                          --
   ≤70%                         11                                                             −28.43 (−30.31 to −26.56)   88.1% and 0.001 and 0.001
                                                                                                                           
  Medication: ACEI                                                                                                         
   \>70%                        --                                                             --                          --
   ≤70%                         17                                                             −25.60 (−27.33 to −23.88)   89.6% and 0.001 and 0.001
                                                                                                                           
  Medication: Statin                                                                                                       
   \>70%                        --                                                             --                          --
   ≤70%                         18                                                             −25.90 (−27.64 to −24.15)   88.4% and 0.001 and 0.001
                                                                                                                           
  Medication: Beta-Blocker                                                                                                 
   \>70%                        --                                                             --                          --
   ≤70%                         17                                                             −25.40 (−27.11 to −23.68)   89.3% and 0.001 and 0.001
                                                                                                                           
  Anti-coagulant status codes                                                                                              
   1                            9                                                              −54.79 (−58.44 to −51.15)   93.4% and 0.001 and 0.001
   2                            3                                                              1.69 (−17.11 to 20.53)      67.3% and 0.047 and 0.860
   3                            3                                                              −3.15 (−17.55 to 11.23)     0.0% and 0.890 and 0.667
   4                            19                                                             −25.27 (−27.00 to −23.53)   90.9% and 0.001 and 0.001
   5                            8                                                              −10.84 (−14.41 to 7.24)     38.3% and 0.124 and 0.001
   6                            3                                                              −6.34 (−21.47 to 8.77)      70.8% and 0.033 and 0.411
                                                                                                                           
  AF                                                                                                                       
   Chronic                      12                                                             −2.15 (−7.34 to 3.02)       35.6% and 0.106 and 0.414
   Non-chronic                  11                                                             −21.73 (−24.45 to −19.01)   95.5% and 0.001 and 0.001
                                                                                                                           
  Type of AF                                                                                                               
   Paroxysmal                   5                                                              −5.29 (−11.24 to 0.64)      67.8% and 0.015 and 0.081
   Persistent                   3                                                              −41.86 (−46.34 to −37.38)   97.4% and 0.001 and 0.001
   Permanent                    5                                                              −4.55 (−11.58 to 2.46)      64.6% and 0.023 and 0.204
                                                                                                                           
  Cigarette smoking                                                                                                        
   \>30%                        9                                                              2.31 (−4.14 to 8.77)        67.3% and 0.002 and 0.482
   ≤30%                         17                                                             −9.11 (−12.70 to −5.52)     46.6% and 0.018 and 0.001
                                                                                                                           
  **Mean platelet volume**                                                                                                 
                                                                                                                           
  Year of publication                                                                                                      
   \>2000                       All of studies: after 2000                                                                 
   ≤2000                                                                                                                   
                                                                                                                           
  Geographic area                                                                                                          
   Asian                        3                                                              1.37 (1.16 to 1.58)         95.9% and 0.001 and 0.001
   European                     16                                                             0.56 (0.51 to 0.61)         93.1% and 0.001 and 0.001
   Africa                       --                                                             --                          --
   North American               --                                                             --                          --
   South American               --                                                             --                          --
   Australia                    --                                                             --                          --
                                                                                                                           
  Design of study                                                                                                          
   Cohort                       4                                                              1.37 (1.14 to 1.60)         94.7% and 0.001 and 0.001
   Case-control                 15                                                             0.57 (0.52 to 0.62)         93.6% and 0.001 and 0.001
                                                                                                                           
  Number of population                                                                                                     
   \>300                        2                                                              0.90 (0.67 to 1.13)         0.0% and 0.666 and 0.001
   ≤300                         17                                                             0.59 (0.54 to 0.64)         94.9% and 0.001 and 0.001
                                                                                                                           
  Mean Age                                                                                                                 
   \>60 years                   15                                                             0.61 (0.56 to 0.66)         94.8% and 0.001 and 0.001
   ≤60 years                    3                                                              0.33 (0.13 to 0.54)         95.2% and 0.001 and 0.001
                                                                                                                           
  Male                                                                                                                     
   \>70%                        4                                                              0.67 (0.50 to 0.83)         95.6% and 0.001 and 0.001
   ≤70%                         14                                                             0.59 (0.54 to 0.64)         94.7% and 0.001 and 0.001
                                                                                                                           
  Diabetes mellitus                                                                                                        
   \>30%                        2                                                              0.59 (0.53 to 0.65)         42.3% and 0.188 and 0.001
   ≤30%                         14                                                             0.60 (0.52 to 0.67)         95.8% and 0.001 and 0.001
                                                                                                                           
  Hypertension                                                                                                             
   \>70%                        --                                                             --                          --
   ≤70%                         16                                                             0.59 (0.55 to 0.64)         95.1% and 0.001 and 0.001
                                                                                                                           
  History of MI                 Studies have not data about history of myocardial infarction                               
                                                                                                                           
  Medication: Diuretic                                                                                                     
   \>70%                        --                                                             --                          --
   ≤70%                         8                                                              0.57 (0.52 to 0.62)         95.5% and 0.001 and 0.001
                                                                                                                           
  Medication: ACEI                                                                                                         
   \>70%                        --                                                             --                          --
   ≤70%                         10                                                             0.60 (0.55 to 0.65)         96.4% and 0.001 and 0.001
                                                                                                                           
  Medication: Statin                                                                                                       
   \>70%                        --                                                             --                          --
   ≤70%                         10                                                             0.66 (0.61 to 0.72)         95.1% and 0.001 and 0.001
                                                                                                                           
  Medication: Beta-Blocker                                                                                                 
   \>70%                        --                                                             --                          --
   ≤70%                         11                                                             0.58 (0.53 to 0.63)         96.4% and 0.001 and 0.001
                                                                                                                           
  Anti-coagulant status codes                                                                                              
   1                            --                                                             --                          --
   2                            1                                                              0.80 (0.26 to 1.33)         --
   3                            2                                                              −0.07 (−0.31 to 0.16)       8.7% and 0.295 and 0.530
   4                            10                                                             0.67 (0.62 to 0.73)         95.1% and 0.001 and 0.001
   5                            5                                                              0.43 (0.33 to 0.53)         94.6% and 0.001 and 0.001
   6                            1                                                              1.10 (0.75 to 1.45)         --
                                                                                                                           
  AF                                                                                                                       
   Chronic                      7                                                              0.58 (0.53 to 0.63)         96.6% and 0.001 and 0.001
   Non-chronic                  3                                                              0.85 (0.58 to 1.13)         88.6% and 0.001 and 0.001
                                                                                                                           
  Type of AF                                                                                                               
   Paroxysmal                   1                                                              1.70 (1.20. to 2.19)        --
   Persistent                   1                                                              0.32 (−0.09 to 0.73)        --
   Permanent                    3                                                              0.39 (0.28 to 0.51)         97.1% and 0.001 and 0.001
                                                                                                                           
  Cigarette smoking                                                                                                        
   \>30%                        8                                                              0.68 (0.62 to 0.74)         94.7% and 0.001 and 0.001
   ≤30%                         7                                                              0.45 (0.36 to 0.54)         94.8% and 0.001 and 0.001
                                                                                                                           
  **BTG**                                                                                                                  
                                                                                                                           
  Year of Publication                                                                                                      
   \>2000                       11                                                             29.31 (28.57 to 30.04)      88.6% and 0.001 and 0.001
   ≤2000                        11                                                             12.67 (11.49 to 13.85)      95.5% and 0.001 and 0.001
                                                                                                                           
  Geographic area                                                                                                          
   Asian                        8                                                              30.31 (29.51 to 31.11)      77% and 0.001 and 0.001
   European                     14                                                             15.91 (14.92 to 16.91)      96.2% and 0.001 and 0.001
   Africa                       --                                                             --                          --
   North American               --                                                             --                          --
   South American               --                                                                                         --
   Australia                    --                                                                                         --
                                                                                                                           
  Design of study                                                                                                          
   Cohort                       All of studies are "case-control"                                                          
   Case-control                                                                                                            
                                                                                                                           
  Number of population                                                                                                     
   \>300                        All of studies are "number less than 300 population"                                       
   ≤300                                                                                                                    
                                                                                                                           
  Mean Age                                                                                                                 
   \>60 years                   11                                                             15.79 (14.74 to 16.84)      94.2% and 0.001 and 0.001
   ≤60 years                    6                                                              13.01 (9.94 to 16.08)       90.1% and 0.001 and 0.001
                                                                                                                           
  Male                                                                                                                     
   \>70%                        3                                                              39.01 (33.37 to 44.65)      0.0% and 0.600 and 0.001
   ≤70%                         9                                                              19.98 (18.28 to 21.68)      90.9% and 0.001 and 0.001
                                                                                                                           
  Diabetes mellitus                                                                                                        
   \>30%                        --                                                             --                          --
   ≤30%                         7                                                              25.36 (23.30 to 27.42)      80.8% and 0.001 and 0.001
                                                                                                                           
  Hypertension                                                                                                             
   \>70%                        --                                                             --                          --
   ≤70%                         7                                                              25.36 (23.30 to 27.42)      80.8% and 0.001 and 0.001
                                                                                                                           
  History of MI                 No Data                                                                                    
                                                                                                                           
  Medication: Diuretic          No Data                                                                                    
                                                                                                                           
  Medication: ACEI                                                                                                         
   \>70%                        No Data                                                                                    
   ≤70%                                                                                                                    
                                                                                                                           
  Medication: Statin                                                                                                       
   \>70%                                                                                                                   No Data
   ≤70%                                                                                                                    
                                                                                                                           
  Medication: Beta-Blocker                                                                                                 
   \>70%                        --                                                             --                          --
   ≤70%                         4                                                              27.17 (23.22 to 31.12)      89.1% and 0.001 and 0.001
                                                                                                                           
  Anti-coagulant status codes                                                                                              
   1                            14                                                             14.70 (13.63 to 15.78)      93.6% and 0.001 and 0.001
   2                            --                                                             --                          --
   3                            1                                                              39.16 (29.56 to 48.75)      --
   4                            3                                                              27.83 (24.92 to 30.73)      85.5% and 0.001 and 0.001
   5                            4                                                              29.83 (29.03 to 30.63)      97.8% and 0.001 and 0.001
   6                            --                                                             --                          --
                                                                                                                           
  AF                                                                                                                       
   Chronic                      8                                                              24.21 (22.11 to 26.30)      96.7% and 0.001 and 0.001
   Non-chronic                  5                                                              17.74 (14.40 to 21.08)      31.3% and 0.213 and 0.001
                                                                                                                           
  Type of AF                                                                                                               
   Paroxysmal                   4                                                              17.60 (13.57 to 21.63)      48.3% and 0.121 and 0.001
   Persistent                   --                                                             --                          --
   Permanent                    4                                                              25.90 (23.39 to 28.40)      80.5% and 0.002 and 0.001
                                                                                                                           
  Cigarette smoking                                                                                                        
   \>30%                        3                                                              39.01 (33.37 to 44.65)      0.0% and 0.600 and 0.001
   ≤30%                         3                                                              18.64 (16.00 to 21.27)      97.2% and 0.001 and 0.001
                                                                                                                           
  **Platelet factor 4**                                                                                                    
                                                                                                                           
  Year of Publication                                                                                                      
   \>2000                       9                                                              6.38 (6.04 to 6.72)         99.8% and 0.001 and 0.001
   ≤2000                        7                                                              1.78 (1.36 to 2.20)         81.6% and 0.001 and 0.001
                                                                                                                           
  Geographic area                                                                                                          
   Asian                        7                                                              6.75 (6.32 to 7.17)         51.5% and 0.054 and 0.001
   European                     9                                                              3.25 (2.91 to 3.59)         99.8% and 0.001 and 0.001
   Africa                       --                                                             --                          --
   North American               --                                                             --                          --
   South American               --                                                                                         --
   Australia                    --                                                                                         --
                                                                                                                           
  Design of study                                                                                                          
   Cohort                       All of studies are "case-control"                                                          
   Case-control                                                                                                            
                                                                                                                           
  Number of population                                                                                                     
   \>300                        All of studies are "number less than 300 population"                                       
   ≤300                                                                                                                    
                                                                                                                           
  Mean Age                                                                                                                 
   \>60 years                   6                                                              2.27 (1.93 to 2.61)         94.6% and 0.001 and 0.001
   ≤60 years                    7                                                              58.31 (55.83 to 60.80)      99.6% and 0.001 and 0.001
                                                                                                                           
  Male                                                                                                                     
   \>70%                        1                                                              2.80 (2.23 to 3.36)         --
   ≤70%                         5                                                              11.60 (9.55 to 13.66)       89.3% and 0.001 and 0.001
                                                                                                                           
  Diabetes mellitus                                                                                                        
   \>30%                        --                                                             --                          --
   ≤30%                         4                                                              15.25 (12.79 to 17.72)      69.6% and 0.020 and 0.001
                                                                                                                           
  Hypertension                                                                                                             
   \>70%                        --                                                             --                          --
   ≤70%                         4                                                              15.25 (12.79 to 17.72)      69.6% and 0.020 and 0.001
                                                                                                                           
  History of MI                                                                                                            
   \>20%                        1                                                              15.55 (11.43 to 19.67)      --
   ≤20%                         1                                                              12.17 (8.38 to 15.95)       --
                                                                                                                           
  Medication: Diuretic          No Data                                                                                    
                                                                                                                           
  Medication: ACEI                                                                                                         
   \>70%                        --                                                             --                          --
   ≤70%                         2                                                              13.71 (10.92 to 16.50)      28.7% and 0.236 and 0.001
                                                                                                                           
  Medication: Statin                                                                                                       
   \>70%                        --                                                             --                          --
   ≤70%                         18                                                             13.71 (10.92 to 16.50)      28.7% and 0.236 and 0.001
                                                                                                                           
  Medication: Beta-Blocker                                                                                                 
   \>70%                        --                                                             --                          --
   ≤70%                         4                                                              15.25 (12.79 to 17.72)      69.6% and 0.020 and 0.001
                                                                                                                           
  Anti-coagulant status codes                                                                                              
   1                            9                                                              1.90 (1.48 to 2.32)         90.6% and 0.001 and 0.001
   2                            --                                                             --                          --
   3                            1                                                              2.80 (2.23 to 3.36)         --
   4                            2                                                              13.71 (10.92 to 16.50)      28.7% and 0.236 and 0.001
   5                            4                                                              8.18 (7.75 to 8.61)         99.9% and 0.001 and 0.001
   6                            --                                                             --                          --
                                                                                                                           
  AF                                                                                                                       
   Chronic                      2                                                              2.93 (2.37 to 3.49)         97.3% and 0.001 and 0.001
   Non-chronic                  5                                                              13.07 (10.71 to 15.43)      23.9% and 0.262 and 0.001
                                                                                                                           
  Type of AF                                                                                                               
   Paroxysmal                   4                                                              11.86 (8.98 to 14.75)       6.1% and 0.363 and 0.001
   Persistent                   1                                                              15.50 (11.43 to 19.67)      --
   Permanent                    1                                                              2.93 (2.37 to 3.49)         97.3% and 0.001 and 0.001
                                                                                                                           
  Cigarette smoking                                                                                                        
   \>30%                        1                                                              2.80 (2.23 to 3.36)         --
   ≤30%                         2                                                              13.71 (10.92 to 16.50)      28.7% and 0.236 and 0.001
                                                                                                                           
  **P-selectin**                                                                                                           
                                                                                                                           
  Year of Publication                                                                                                      
   \>2000                       23                                                             4.92 (4.37 to 5.47)         98.6% and 0.001 and 0.001
   ≤2000                        1                                                              −71.00 (−104.1 to −37.80)   --
                                                                                                                           
  Geographic area                                                                                                          
   Asian                        3                                                              1.90 (0.42 to 3.38)         78.9% and 0.009 and 0.012
   European                     19                                                             5.30 (4.71 to 5.89)         98.8% and 0.001 and 0.001
   Africa                       1                                                              47.90 (29.57 to 66.22)      --
   North American               --                                                             --                          --
   South American               1                                                              74.0 (46.63 to 101.36)      --
   Australia                    --                                                                                         --
                                                                                                                           
  Design of study                                                                                                          
   Cohort                       3                                                              −0.27 (−1.16 to 0.61)       81.2% and 0.005 and 0.547
   Case-control                 21                                                             8.04 (7.35 to 8.74)         98.6% and 0.001 and 0.001
                                                                                                                           
  Number of population                                                                                                     
   \>300                        1                                                              −0.50 (−2.61 to 1.61)       --
   ≤300                         23                                                             5.29 (4.72 to 5.86)         98.6% and 0.001 and 0.001
                                                                                                                           
  Mean Age                                                                                                                 
   \>60 years                   19                                                             4.95 (4.38 to 5.53)         98.8% and 0.001 and 0.001
   ≤60 years                    3                                                              4.46 (2.38 to 6.54)         95.2% and 0.001 and 0.001
                                                                                                                           
  Male                                                                                                                     
   \>70%                        8                                                              5.42 (4.72 to 6.12)         99.5% and 0.001 and 0.001
   ≤70%                         14                                                             4.09 (3.19 to 4.99)         95.5% and 0.001 and 0.001
                                                                                                                           
  Diabetes mellitus                                                                                                        
   \>30%                        --                                                             --                          --
   ≤30%                         15                                                             4.70 (4.08 to 5.31)         99.0% and 0.001 and 0.001
                                                                                                                           
  Hypertension                                                                                                             
   \>70%                        --                                                             --                          --
   ≤70%                         16                                                             5.54 (4.93 to 6.15)         99.0% and 0.001 and 0.001
                                                                                                                           
  History of MI                                                                                                            
   \>20%                        1                                                              −0.50 (−2.61 to 1.61)       --
   ≤20%                         2                                                              4.11 (1.41 to 6.82)         87.1% and 0.005 and 0.003
                                                                                                                           
  Medication: Diuretic                                                                                                     
   \>70%                        --                                                             --                          --
   ≤70%                         7                                                              5.24 (4.53 to 5.96)         99.0% and 0.001 and 0.001
                                                                                                                           
  Medication: ACEI                                                                                                         
   \>70%                        --                                                             --                          --
   ≤70%                         8                                                              5.25 (4.54 to 5.96)         98.9% and 0.001 and 0.001
                                                                                                                           
  Medication: Statin                                                                                                       
   \>70%                        --                                                             --                          --
   ≤70%                         6                                                              4.60 (3.87 to 5.34)         98.8% and 0.001 and 0.001
                                                                                                                           
  Medication: Beta-Blocker                                                                                                 
   \>70%                        --                                                             --                          --
   ≤70%                         10                                                             3.67 (3.02 to 4.33)         98.0% and 0.001 and 0.001
                                                                                                                           
  Anti-coagulant status codes                                                                                              
   1                            5                                                              5.46 (2.88 to 8.03)         97.2% and 0.001 and 0.001
   2                            --                                                             --                          --
   3                            6                                                              9.20 (7.99 to 10.42)        99.5% and 0.001 and 0.001
   4                            10                                                             4.19 (3.50 to 4.87)         98% and 0.001 and 0.001
   5                            3                                                              0.81 (−0.85 to 2.47)        91.4% and 0.001 and 0.342
   6                            --                                                             --                          --
                                                                                                                           
  AF                                                                                                                       
   Chronic                      6                                                              5.94 (4.28 to 7.60)         99.4% and 0.001 and 0.001
   Non-chronic                  8                                                              3.09 (1.94 to 4.23)         92.2% and 0.001 and 0.001
                                                                                                                           
  Type of AF                                                                                                               
   Paroxysmal                   2                                                              1.40 (−0.58 to 3.39)        2.1% and 0.312 and 0.166
   Persistent                   2                                                              8.17 (6.10 to 10.25)        96.2% and 0.001 and 0.001
   Permanent                    5                                                              6.13 (4.47 to 7.79)         99.5% and 0.001 and 0.001
                                                                                                                           
  Cigarette smoking                                                                                                        
   \>30%                        2                                                              4.76 (2.68 to 6.84)         95.4% and 0.001 and 0.001
   ≤30%                         15                                                             5.41 (4.55 to 6.27)         
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###### 

Characteristics of included studies for meta-analysis of association of platelets characteristics and AF.

  First Author                                                                     Year   Country   Design         N-AF   N-SR   Age-AF   Age-SR   Male-AF   Male-SR   AC-AF   AC-SR   Type of AF   NOS
  -------------------------------------------------------------------------------- ------ --------- -------------- ------ ------ -------- -------- --------- --------- ------- ------- ------------ -----
  Karatas \[[@b20-medscimonitbasicres-23-58]\]                                     2016   Turkey    Case-control   40     581    65.7     56.4     70        75        100     100     ND           8
  Drabik \[[@b21-medscimonitbasicres-23-58]\]                                      2015   Poland    Case-control   47     50     60.8     59.4     65.9      64        38.3    26      Persistent   9
  Drabik \[[@b21-medscimonitbasicres-23-58]\]                                      2015   Poland    Case-control   41     50     60.6     59.4     46.3      64        51.2    26      Paroxysmal   9
  Idriss \[[@b22-medscimonitbasicres-23-58]\]                                      2015   Egypt     Case-control   21     20     34.2     29.3     28.5      70        33.3    0       ND           7
  Akdag \[[@b23-medscimonitbasicres-23-58]\]                                       2015   Turkey    Case-control   96     52     63.6     64.5     64        56        54.1    ND      Combined     9
  Akyuz \[[@b24-medscimonitbasicres-23-58]\]                                       2015   Turkey    Case-control   40     50     63       61.5     72.5      72        20      14      Combined     7
  Chavaria \[[@b25-medscimonitbasicres-23-58]\]                                    2015   USA       Case-control   40     250    70.6     60.7     65        84        ND      ND      ND           6
  Erdogan \[[@b26-medscimonitbasicres-23-58]\]                                     2014   Turkey    Case-control   34     33     70.5     68.6     47        51.5      66.6    0       Permanent    9
  Xu (without comorbidities) \[[@b27-medscimonitbasicres-23-58]\]                  2014   China     Cohort         57     58     65.1     67       50.9      50        50.9    15.5    ND           7
  Xu (with comorbidities) \[[@b27-medscimonitbasicres-23-58]\]                     2014   China     Cohort         57     58     68.95    67       52.6      50        49.1    15.5    ND           7
  Acet (PAF) \[[@b28-medscimonitbasicres-23-58]\]                                  2014   Turkey    Case-control   71     63     63       61.1     42        46        ND      ND      Paroxysmal   9
  Acet (persistent and permanent) \[[@b28-medscimonitbasicres-23-58]\]             2014   Turkey    Case-control   63     63     64.6     61.1     41        46        ND      ND      Combined     9
  Arik (with INR 2--3) \[[@b29-medscimonitbasicres-23-58]\]                        2014   Turkey    Case-control   125    123    70.4     68.9     41.6      39.8      ND      ND      Permanent    8
  Arik (with abnormal INR) \[[@b29-medscimonitbasicres-23-58]\]                    2014   Turkey    Case-control   125    123    70       68.9     36        39.8      ND      ND      Permanent    8
  Distelmaier \[[@b30-medscimonitbasicres-23-58]\]                                 2014   USA       Case-control   66     132    73.5     73.5     61        61        ND      ND      ND           7
  Gungor \[[@b31-medscimonitbasicres-23-58]\]                                      2014   Turkey    Case-control   117    60     48.3     46.1     60.6      55        75.2    8.3     Combined     9
  Sonmez \[[@b32-medscimonitbasicres-23-58]\]                                      2014   Turkey    Cohort         52     33     70       70       34.6      39.3      59.6    36.3    Persistent   7
  Ulu \[[@b33-medscimonitbasicres-23-58]\]                                         2014   Turkey    Case-control   25     32     ND       ND       ND        ND        ND      ND      ND           7
  Turgut \[[@b34-medscimonitbasicres-23-58]\]                                      2013   Turkey    Case-control   81     81     64       62       51        53        28      20      ND           7
  Jaremo (healthy control) \[[@b35-medscimonitbasicres-23-58]\]                    2013   Sweden    Cohort         58     24     69       66       79.3      54.1      12.06   0       ND           8
  Jaremo (disease control) \[[@b35-medscimonitbasicres-23-58]\]                    2013   Sweden    Cohort         58     72     69       74       79.3      56.9      12.06   41.6    ND           8
  Berge \[[@b36-medscimonitbasicres-23-58]\]                                       2013   Norway    Cohort         63     126    75       75       71.4      70.6      8       33      Combined     9
  Ertas (without stroke) \[[@b37-medscimonitbasicres-23-58]\]                      2013   Turkey    Case-control   87     24     69       38       44        58        58      ND      ND           6
  Ertas (with stroke) \[[@b37-medscimonitbasicres-23-58]\]                         2013   Turkey    Case-control   39     24     71       38       36        58        51      ND      ND           6
  Sahin \[[@b38-medscimonitbasicres-23-58]\]                                       2013   Turkey    Case-control   72     72     65.1     64.7     48.2      51.3      ND      ND      Persistent   7
  Tekin \[[@b39-medscimonitbasicres-23-58]\]                                       2013   Turkey    Case-control   107    112    74       73       31        40        ND      ND      ND           7
  Turfan (without CVA) \[[@b40-medscimonitbasicres-23-58]\]                        2013   Turkey    Cohort         77     58     63       56       57.4      51.7      44.3    0       ND           7
  Turfan (with CVA) \[[@b40-medscimonitbasicres-23-58]\]                           2013   Turkey    Cohort         63     58     69       56       52.4      51.7      41.3    0       ND           7
  Feng \[[@b41-medscimonitbasicres-23-58]\]                                        2012   China     Case-control   185    189    65.9     65.7     62.7      60.8      76.8    83.1    Combined     8
  Acevedo \[[@b42-medscimonitbasicres-23-58]\]                                     2012   Chile     Case-control   130    20     67       ND       ND        ND        0       0       Combined     ND
  Hayashi \[[@b43-medscimonitbasicres-23-58]\]                                     2011   Japan     Case-control   14     13     53.1     62.8     93        92        100     100     Paroxysmal   7
  Hayashi \[[@b43-medscimonitbasicres-23-58]\]                                     2011   Japan     Case-control   14     13     60.1     62.8     93        92        100     100     ND           7
  Fu \[[@b44-medscimonitbasicres-23-58]\]                                          2011   China     Case-control   90     79     54.1     54.8     70        57        22      0       Combined     8
  Hou (disease control) \[[@b45-medscimonitbasicres-23-58]\]                       2010   China     Case-control   26     26     65.2     64.5     57.6      57.6      7.6     11.5    ND           8
  Hou (healthy control) \[[@b45-medscimonitbasicres-23-58]\]                       2010   China     Case-control   26     26     65.2     65.4     57.6      57.6      7.6     0       ND           8
  Alberti \[[@b46-medscimonitbasicres-23-58]\]                                     2009   Italy     Case-control   17     34     68.1     60.8     94.1      23.5      0       0       Persistent   7
  Choudhury (disease control) \[[@b47-medscimonitbasicres-23-58]\]                 2008   UK        Case-control   121    71     62.58    64.04    76        72        37.2    47.4    ND           6
  Choudhury (healthy control) \[[@b47-medscimonitbasicres-23-58]\]                 2008   UK        Case-control   121    65     62.58    62.03    76        68        37.2    0       ND           6
  Colkesen \[[@b48-medscimonitbasicres-23-58]\]                                    2008   Turkey    Case-control   103    87     63       45       55        21        50      14      Paroxysmal   8
  Blann \[[@b49-medscimonitbasicres-23-58]\]                                       2008   UK        Case-control   54     28     65       64       64.8      60.7      60      0       ND           6
  Topaloglu (disease control) \[[@b50-medscimonitbasicres-23-58]\]                 2007   Turkey    Case-control   18     28     37       32       ND        ND        ND      ND      ND           6
  Topaloglu (healthy control) \[[@b50-medscimonitbasicres-23-58]\]                 2007   Turkey    Case-control   18     20     37       35       ND        ND        ND      ND      ND           6
  Yip \[[@b51-medscimonitbasicres-23-58]\]                                         2006   Taiwan    Case-control   62     20     66.2     65.3     66.1      60        58.1    0       ND           7
  Heeringa \[[@b52-medscimonitbasicres-23-58]\]                                    2006   UK        Cohort         162    324    78       77       51        51        ND      ND      ND           8
  Inoue (with comorbidities) \[[@b53-medscimonitbasicres-23-58]\]                  2004   Japan     Case-control   159    92     ND       ND       ND        ND        ND      ND      ND           7
  Inoue (lone AF) \[[@b53-medscimonitbasicres-23-58]\]                             2004   Japan     Case-control   87     19     ND       ND       ND        ND        ND      ND      ND           7
  Conway \[[@b54-medscimonitbasicres-23-58]\]                                      2004   UK        Case-control   106    41     69       67       63        61        86      0       Permanent    6
  Conway \[[@b55-medscimonitbasicres-23-58]\]                                      2004   Turkey    Case-control   37     37     67       68       72.9      67.56     ND      ND      Persistent   6
  Atalar (paroxysmal AF) \[[@b56-medscimonitbasicres-23-58]\]                      2003   Turkey    Case-control   15     22     45       47       60        63.6      0       0       Paroxysmal   6
  Atalar (permanent AF) \[[@b56-medscimonitbasicres-23-58]\]                       2003   Turkey    Case-control   25     22     51       47       64        63.6      0       0       Permanent    6
  Kamath \[[@b57-medscimonitbasicres-23-58]\]                                      2003   UK        Case-control   31     31     61       66       61.3      41.9      0       0       Combined     6
  Kamath \[[@b57-medscimonitbasicres-23-58]\]                                      2003   UK        Case-control   93     31     66       66       63.4      41.9      0       0       Permanent    6
  Kamath \[[@b58-medscimonitbasicres-23-58]\]                                      2002   UK        Case-control   29     29     61       65       55.17     41.3      37.9    0       Paroxysmal   7
  Kamath \[[@b58-medscimonitbasicres-23-58]\]                                      2002   UK        Case-control   87     29     65       65       63.2      41.3      37.9    0       Permanent    7
  Kamath \[[@b59-medscimonitbasicres-23-58]\]                                      2002   UK        Case-control   93     50     70       70       62.4      64        0       0       ND           6
  Kamath \[[@b60-medscimonitbasicres-23-58]\]                                      2002   UK        Case-control   34     23     73       ND       20        ND        0       0       ND           6
  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  2001   UK        Case-control   23     20     65       63       69.6      85        69.6    0       Paroxysmal   8
  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  2001   UK        Case-control   23     20     65       63       69.6      85        100     0       Persistent   8
  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  2001   UK        Case-control   23     20     67       63       69.6      85        100     0       Permanent    8
  Mondillo \[[@b62-medscimonitbasicres-23-58]\]                                    2000   Italy     Case-control   45     35     67.6     66.3     80        85.7      55      0       Permanent    7
  Li-Saw-Hee \[[@b63-medscimonitbasicres-23-58]\]                                  2000   UK        Case-control   52     60     68       66       80        75        0       0       ND           6
  Li-Saw-Hee \[[@b64-medscimonitbasicres-23-58]\]                                  1999   UK        Case-control   25     25     60       58       20        20        ND      ND      ND           6
  Minamino \[[@b65-medscimonitbasicres-23-58]\]                                    1999   UK        Case-control   28     28     64       64       71.4      71.4      7       14      ND           6
  Minamino \[[@b66-medscimonitbasicres-23-58]\]                                    1997   Japan     Case-control   45     45     63       63       73.3      73.3      ND      ND      ND           6
  Kahn \[[@b67-medscimonitbasicres-23-58]\]                                        1997   Canada    Case-control   50     31     ND       ND       ND        ND        0       0       ND           7
  Sohara \[[@b68-medscimonitbasicres-23-58]\]                                      1997   Japan     Case-control   21     9      59.1     59       ND        ND        0       0       Paroxysmal   6
  Lip GY \[[@b69-medscimonitbasicres-23-58]\]                                      1996   UK        Case-control   51     26     70.4     ND       ND        ND        0       0       ND           6
  Nagao \[[@b70-medscimonitbasicres-23-58]\]                                       1995   Japan     Case-control   17     19     81.5     78.4     47.1      47        0       0       ND           8
  Sohara \[[@b71-medscimonitbasicres-23-58]\]                                      1994   Japan     Case-control   19     9      60       ND       76.9      ND        0       0       Paroxysmal   6
  Gustafsson (with stroke) \[[@b72-medscimonitbasicres-23-58]\]                    1990   Sweden    Case-control   20     40     77       77       ND        ND        0       0       ND           8
  Gustafsson (without stroke) \[[@b72-medscimonitbasicres-23-58]\]                 1990   Sweden    Case-control   20     40     77       77       ND        ND        0       0       ND           8
  Yamauchi (without valvular heart disease) \[[@b73-medscimonitbasicres-23-58]\]   1986   Japan     Case-control   73     57     47       36       ND        89.5      0       0       ND           6
  Yamauchi (with valvular heart disease) \[[@b73-medscimonitbasicres-23-58]\]      1986   Japan     Case-control   26     57     55       36       ND        89.5      0       0       ND           6

###### 

Information about markers and their levels in each study.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                                                                     markers               Levels
  -------------------------------------------------------------------------------- --------------------- --------------------------------------------------------
  Karatas \[[@b20-medscimonitbasicres-23-58]\]                                     PC, MPV, PDW          PC \[AF: 230±69.3 *vs.* SR: 240±77.5\]\
                                                                                                         MPV \[AF: 9.5±1.7 *vs.* SR: 8.7±1\]\
                                                                                                         PDW \[AF: 13.9±1.7 *vs.* SR: 13.4±1.4\]

  Drabik \[[@b21-medscimonitbasicres-23-58]\]                                      PC, PF4               PC \[AF: 202±20.5 *vs.* SR: 219±16.5\]\
                                                                                                         PF4 \[AF: 66.1±10.25 *vs.* SR: 50.55±10.45\]

  Drabik \[[@b21-medscimonitbasicres-23-58]\]                                      PC, PF4               PC \[AF: 210.25±15.75 *vs.* SR: 219±16.5\]\
                                                                                                         PF4 \[AF: 62.72±7.95 *vs.* SR: 50.55±10.45\]

  Idriss \[[@b22-medscimonitbasicres-23-58]\]                                      P-selectin            P-selectin \[AF: 85.9±42.1 *vs.* SR: 38±7.8\]

  Akdag \[[@b23-medscimonitbasicres-23-58]\]                                       PC, MPV               PC \[AF: 265.5±73.4 *vs.* SR: 248.2±67.2\]\
                                                                                                         MPV \[AF: 8.9±1.1 *vs.* SR: 7.8±1\]

  Akyuz \[[@b24-medscimonitbasicres-23-58]\]                                       PC, MPV               PC \[AF: 277±79 *vs.* SR: 264±82\]\
                                                                                                         MPV \[AF: 9.8±0.6 *vs.* SR: 8.4±0.6\]

  Chavaria \[[@b25-medscimonitbasicres-23-58]\]                                    PC                    PC \[AF: 242.2±54.1 *vs.* SR: 243.2±66.2\]

  Erdogan \[[@b26-medscimonitbasicres-23-58]\]                                     PC, MPV, P-selectin   PC \[AF: 245.6±114.9 *vs.* SR: 238.4±66.6\]\
                                                                                                         MPV \[AF: 7.82±1.2 *vs.* SR: 7.68±0.7\]\
                                                                                                         P-selectin \[AF: 25.86±11.89 *vs.* SR: 23.95±8.49\]

  Xu (without comorbidities) \[[@b27-medscimonitbasicres-23-58]\]                  PC, MPV               PC \[AF: 205±31 *vs.* SR: 209±41\]\
                                                                                                         MPV \[AF: 10.6±1.9 *vs.* SR: 8.7±0.8\]

  Xu (with comorbidities) \[[@b27-medscimonitbasicres-23-58]\]                     PC, MPV               PC \[AF: 206±42 *vs.* SR: 209±41\]\
                                                                                                         MPV \[AF: 11.7±2 *vs.* SR: 8.7±0.8\]

  Acet (PAF) \[[@b28-medscimonitbasicres-23-58]\]                                  PC                    PC \[AF: 248.9±59 *vs.* SR: 259.8±95.9\]

  Acet (persistent and permanent) \[[@b28-medscimonitbasicres-23-58]\]             PC                    PC \[AF: 268±98 *vs.* SR: 259.8±95.9\]

  Arik (with INR 2--3) \[[@b29-medscimonitbasicres-23-58]\]                        PC, MPV, PDW          PC \[AF: 259±54.3 *vs.* SR: 255.75±41.5\]\
                                                                                                         MPV \[AF: 7.56±0.63 *vs.* SR: 7.63±0.68\]\
                                                                                                         PDW \[AF: 17.05±0.86 *vs.* SR: 17.52±0.71\]

  Arik (with abnormal INR) \[[@b29-medscimonitbasicres-23-58]\]                    PC, MPV, PDW          PC \[AF: 238.75±41.16 *vs.* SR: 255.75±41.5\]\
                                                                                                         MPV \[AF: 8.26±0.63 *vs.* SR: 7.63±0.68\]\
                                                                                                         PDW \[AF: 17.50±1.13 *vs.* SR: 17.52±0.71\]

  Distelmaier \[[@b30-medscimonitbasicres-23-58]\]                                 PC                    PC \[AF: 202±14.75 *vs.* SR: 215±14.16\]

  Gungor \[[@b31-medscimonitbasicres-23-58]\]                                      PC, MPV               PC \[AF: 249.4±59.4 *vs.* SR: 253.4±61.1\]\
                                                                                                         MPV \[AF: 8.99±0.65 *vs.* SR: 9.14±0.98\]

  Sonmez \[[@b32-medscimonitbasicres-23-58]\]                                      PC                    PC \[AF: 231±60 *vs.* SR: 247±67\]

  Ulu \[[@b33-medscimonitbasicres-23-58]\]                                         PC, MPV               PC \[AF: 236.4±63.9 *vs.* SR: 233.3±86.2\]\
                                                                                                         MPV \[AF: 11.47±0.93 *vs.* SR: 10.37±1.07\]

  Turgut \[[@b34-medscimonitbasicres-23-58]\]                                      PC, MPV               PC \[AF: 274±82 *vs.* SR: 253±83\]\
                                                                                                         MPV \[AF: 9±0.2 *vs.* SR: 8.4±0.2\]

  Jaremo (healthy control) \[[@b35-medscimonitbasicres-23-58]\]                    PC                    PC \[AF: 241±64 *vs.* SR: 260±78\]

  jaremo (disease control) \[[@b35-medscimonitbasicres-23-58]\]                    PC, P-selectin        PC \[AF: 241±64 *vs.* SR: 265±84\]\
                                                                                                         P-selectin \[AF: 102±53 *vs.* 74±44\]

  Berge \[[@b36-medscimonitbasicres-23-58]\]                                       PC, P-selectin        PC \[AF: 230±7.5 *vs.* SR: 261.25±4.16\]\
                                                                                                         P-selectin \[AF: 31.2±3.72 *vs.* 31.52±2.05\]

  Ertas (without stroke) \[[@b37-medscimonitbasicres-23-58]\]                      PC                    PC \[AF: 232±55 *vs.* 258±54\]

  Ertas (with stroke) \[[@b37-medscimonitbasicres-23-58]\]                         PC                    PC \[AF: 240±82 *vs.* 258±54\]

  Sahin \[[@b38-medscimonitbasicres-23-58]\]                                       MPV                   MPV \[AF: 8.31±1.12 *vs.* SR: 7.99±1.39\]

  Tekin \[[@b39-medscimonitbasicres-23-58]\]                                       PC, MPV               PC \[AF: 242±90 *vs.* SR: 243±67\]\
                                                                                                         MPV \[AF: 9.49±1.08 *vs.* SR: 9.09±1.13\]

  Turfan (without CVA) \[[@b40-medscimonitbasicres-23-58]\]                        PC, MPV               PC \[AF: 264±94 *vs.* SR: 213±72\]\
                                                                                                         MPV \[AF: 9.1±1 *vs.* SR: 8.6±1.3\]

  Turfan (with CVA) \[[@b40-medscimonitbasicres-23-58]\]                           PC, MPV               PC \[AF: 245±73 *vs.* SR: 213±72\]\
                                                                                                         MPV \[AF: 9.7±0.9 *vs.* SR: 8.6±1.3\]

  Feng \[[@b41-medscimonitbasicres-23-58]\]                                        PC, MPV               PC \[AF: 213.3±82.5 *vs.* SR: 217.6±81.7\]\
                                                                                                         MPV \[AF: 9.95±1.32 *vs.* SR: 9.02±1.16\]

  Acevedo \[[@b42-medscimonitbasicres-23-58]\]                                     P-selectin            P-selectin \[AF: 219±141 *vs.* 145±29\]

  Hayashi \[[@b43-medscimonitbasicres-23-58]\]                                     PC                    PC \[AF: 260±83 *vs.* 190±77\]

  Hayashi \[[@b43-medscimonitbasicres-23-58]\]                                     PC                    PC \[AF: 200±14 *vs.* 258±54\]

  Fu \[[@b44-medscimonitbasicres-23-58]\]                                          PC, P-selectin        PC \[AF: 210±55.5 *vs.* SR: 221.1±51.1\]\
                                                                                                         P-selectin \[AF: 33.4±7.4 *vs.* 29.2±6.5\]

  Hou (disease control) \[[@b45-medscimonitbasicres-23-58]\]                       P-selectin            P-selectin \[AF: 32±5 *vs.* 32±4.9\]

  Hou (healthy control) \[[@b45-medscimonitbasicres-23-58]\]                       P-selectin            P-selectin \[AF: 32±5 *vs.* 33±7\]

  Alberti \[[@b46-medscimonitbasicres-23-58]\]                                     PC                    PC \[AF: 185.6±10 *vs.* 243.3±9.5\]

  Choudhury (disease control) \[[@b47-medscimonitbasicres-23-58]\]                 PC, MPV, P-selectin   PC \[AF: 259.9±66.3 *vs.* SR: 261.1±63.4\]\
                                                                                                         MPV \[AF: 7.6±1.4 *vs.* SR: 7.8±0.9\]\
                                                                                                         P-selectin \[AF: 61±7 *vs.* SR: 55.25±6.8\]

  Choudhury (healthy control) \[[@b47-medscimonitbasicres-23-58]\]                 PC, MPV, P-selectin   PC \[AF: 259.9±66.3 *vs.* SR: 266.9±56.1\]\
                                                                                                         MPV \[AF: 7.6±1.4 *vs.* SR: 7.4±0.97\]\
                                                                                                         P-selectin \[AF: 61±7 *vs.* SR: 40.75±5.25\]

  Colkesen \[[@b48-medscimonitbasicres-23-58]\]                                    PC, MPV               PC \[AF: 242±73 *vs.* SR: 236±53\]\
                                                                                                         MPV \[AF: 10±2 *vs.* SR: 8.3±1.5\]

  Blann \[[@b49-medscimonitbasicres-23-58]\]                                       P-selectin            P-selectin \[AF: 72.5±7.5 *vs.* SR: 46.25±6.25\]

  Topaloglu (disease control) \[[@b50-medscimonitbasicres-23-58]\]                 PF4                   PF4 \[AF: 115.39±7.56 *vs.* SR: 97.96±25.51\]

  Topaloglu (healthy control) \[[@b50-medscimonitbasicres-23-58]\]                 PF4                   PF4 \[AF: 115.39±7.56 *vs.* SR: 6.95±2.49\]

  Yip \[[@b51-medscimonitbasicres-23-58]\]                                         PC                    PC \[AF: 204±57 *vs.* SR: 209±49\]

  Heeringa \[[@b52-medscimonitbasicres-23-58]\]                                    P-selectin            P-selectin \[AF: 31.3±10.1 *vs.* SR: 31.8±13.1\]

  Inoue (with comorbidities) \[[@b53-medscimonitbasicres-23-58]\]                  BTG, PF4              BTG \[AF: 74.5±3.3 *vs.* SR: 43.9±3.3\]\
                                                                                                         PF4 \[AF: 21.6±1.5 *vs.* SR: 14.7±1.9\]

  Inoue (lone AF) \[[@b53-medscimonitbasicres-23-58]\]                             BTG, PF4              BTG \[AF: 77±4.9 *vs.* SR: 46.3±5.5\]\
                                                                                                         PF4 \[AF: 23.1±2.1 *vs.* SR: 17.7±3.1\]

  Conway \[[@b54-medscimonitbasicres-23-58]\]                                      P-selectin            P-selectin \[AF: 53.5±4 *vs.* SR: 50.75±6.75\]

  Conway \[[@b55-medscimonitbasicres-23-58]\]                                      P-selectin            P-selectin \[AF: 54.75±5.75 *vs.* SR: 51.25±6.25\]

  Atalar (paroxysmal AF) \[[@b56-medscimonitbasicres-23-58]\]                      BTG, PF4              BTG \[AF: 175.35±11.55 *vs.* SR: 161.7±8.4\]\
                                                                                                         PF4 \[AF: 72.45±11.55 *vs.* SR: 56.7±12.6\]

  Atalar (permanent AF) \[[@b56-medscimonitbasicres-23-58]\]                       BTG, PF4              BTG \[AF: 191.1±14.7 *vs.* SR: 161.7±8.4\]\
                                                                                                         PF4 \[AF: 81.9±12.6 *vs.* SR: 56.7±12.6\]

  Kamath \[[@b57-medscimonitbasicres-23-58]\]                                      PC, BTG, P-selectin   PC \[AF: 280±81 *vs.* SR: 253±51\]\
                                                                                                         BTG \[AF: 90.03±13.3 *vs.* SR: 71.98±10.5\]\
                                                                                                         P-selectin \[AF: 38±6 *vs.* SR: 36±11\]

  Kamath \[[@b57-medscimonitbasicres-23-58]\]                                      PC, BTG, P-selectin   PC \[AF: 264±75 *vs.* SR: 253±51\]\
                                                                                                         BTG \[AF: 92.13±11.02 *vs.* SR: 71.98±10.5\]\
                                                                                                         P-selectin \[AF: 39±10 *vs.* SR: 36±11\]

  Kamath \[[@b58-medscimonitbasicres-23-58]\]                                      PC, BTG, P-selectin   PC \[AF: 279±73 *vs.* SR: 252±53\]\
                                                                                                         BTG \[AF: 89.51±13.9 *vs.* SR: 66.93±8.13\]\
                                                                                                         P-selectin \[AF: 38±11 *vs.* SR: 34±10\]

  Kamath \[[@b58-medscimonitbasicres-23-58]\]                                      PC, BTG, P-selectin   PC \[AF: 266±76 *vs.* SR: 252±53\]\
                                                                                                         BTG \[AF: 93.97±10.5 *vs.* SR: 66.93±8.13\]\
                                                                                                         P-selectin \[AF: 39±10 *vs.* SR: 34±10\]

  Kamath \[[@b59-medscimonitbasicres-23-58]\]                                      PC, BTG               PC \[AF: 253±77 *vs.* SR: 261±62\]\
                                                                                                         BTG \[AF: 92.4±11.9 *vs.* SR: 69.3±10.5\]

  Kamath \[[@b60-medscimonitbasicres-23-58]\]                                      PC, BTG, P-selectin   PC \[AF: 253±67 *vs.* SR: 270±49\]\
                                                                                                         BTG \[AF: 88.2±16.8 *vs.* SR: 67.72±11.5\]\
                                                                                                         P-selectin \[AF: 37±10 *vs.* SR: 36±9\]

  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  P-selectin            P-selectin \[AF: 37±3 *vs.* SR: 36±4\]

  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  P-selectin            P-selectin \[AF: 50.5±6.5 *vs.* SR: 36±4\]

  Li-Saw-Hee \[[@b61-medscimonitbasicres-23-58]\]                                  P-selectin            P-selectin \[AF: 216.5±30.5 *vs.* SR: 36±4\]

  Mondillo \[[@b62-medscimonitbasicres-23-58]\]                                    BTG, PF4              BTG \[AF: 80.11±31.29 *vs.* SR: 40.95±8.75\]\
                                                                                                         PF4 \[AF: 6.82±1.68 *vs.* SR: 4.02±0.84\]

  Li-Saw-Hee \[[@b63-medscimonitbasicres-23-58]\]                                  P-selectin            P-selectin \[AF: 205.25±47.75 *vs.* SR: 125.75±17.25\]

  Li-Saw-Hee \[[@b64-medscimonitbasicres-23-58]\]                                  BTG, P-selectin       BTG \[AF: 34±6 *vs.* SR: 33±11\]\
                                                                                                         P-selectin \[AF: 73±33 *vs.* SR: 144±78\]

  Minamino \[[@b65-medscimonitbasicres-23-58]\]                                    BTG                   BTG \[AF: 84±19.45 *vs.* SR: 43.22±8.32\]

  Minamino \[[@b66-medscimonitbasicres-23-58]\]                                    BTG                   BTG \[AF: 87.65±47.4 *vs.* SR: 55.72±22.02\]

  Kahn \[[@b67-medscimonitbasicres-23-58]\]                                        PC                    PC \[AF: 230±98 *vs.* SR: 233±49\]

  Sohara \[[@b68-medscimonitbasicres-23-58]\]                                      BTG, PF4              BTG \[AF: 38±27.3 *vs.* SR: 22.8±7.85\]\
                                                                                                         PF4 \[AF: 16.4±18.2 *vs.* SR: 3.37±2.26\]

  Lip GY \[[@b69-medscimonitbasicres-23-58]\]                                      PC, BTG               PC \[AF: 242±67 *vs.* SR: 224±63\]\
                                                                                                         BTG \[AF: 187±30 *vs.* SR: 99.75±25.25\]

  Nagao \[[@b70-medscimonitbasicres-23-58]\]                                       BTG, PF4              BTG \[AF: 43.8±23.2 *vs.* SR: 31.9±12.7\]\
                                                                                                         PF4 \[AF: 9.06±7.04 *vs.* SR: 5.68±3.53\]

  Sohara \[[@b71-medscimonitbasicres-23-58]\]                                      BTG, PF4              BTG \[AF: 31.1±29.9 *vs.* SR: 22.8±7.8\]\
                                                                                                         PF4 \[AF: 9.8±15.9 *vs.* SR: 3.4±2.2\]

  Gustafsson (with stroke) \[[@b72-medscimonitbasicres-23-58]\]                    PC, BTG, PF4          PC \[AF: 179±18.5 *vs.* SR: 238.75±15.75\]\
                                                                                                         BTG \[AF: 40.1±5.8 *vs.* SR: 25.47±2.62\]\
                                                                                                         PF4 \[AF: 5.77±2.02 *vs.* SR: 2.55±0.45\]

  Gustafsson (without stroke) \[[@b72-medscimonitbasicres-23-58]\]                 PC, BTG, PF4          PC \[AF: 172.25±8.75 *vs.* SR: 238.75±15.75\]\
                                                                                                         BTG \[AF: 36.25±2.75 *vs.* SR: 25.47±2.62\]\
                                                                                                         PF4 \[AF: 3.77±1.07 *vs.* SR: 2.55±0.45\]

  Yamauchi (without valvular heart disease) \[[@b73-medscimonitbasicres-23-58]\]   BTG, PF4              BTG \[AF: 49.4±35.8 *vs.* SR: 31.2±14\]\
                                                                                                         PF4 \[AF: 18.6±27.2 *vs.* SR: 11.6±8.2\]

  Yamauchi (with valvular heart disease) \[[@b73-medscimonitbasicres-23-58]\]      BTG, PF4              BTG \[AF: 64.1±52.8 *vs.* SR: 31.2±14\]\
                                                                                                         PF4 \[AF: 34.1±45.5 *vs.* SR: 11.6±8.2\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Included studies about relationship between platelet characteristics with clinical adverse events in patients with AF.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author                                      Country and year   Study design   Number   Mean age   AC in patients with adverse events   AC in patients without adverse events   Platelet markers
  ------------------------------------------------- ------------------ -------------- -------- ---------- ------------------------------------ --------------------------------------- --------------------------------------------
  Bayar \[[@b74-medscimonitbasicres-23-58]\]        Turkey-2015        Case-control   90       65.3       --                                   --                                      MPV \[AF: 11.1±1.3 *vs.* SR: 9.1±1\]

  Ertas \[[@b37-medscimonitbasicres-23-58]\]        Turkey-2013        Case-control   126      70         58                                   51                                      PC \[AF: 240±82 *vs.* SR: 232±55\]

  Turfan \[[@b40-medscimonitbasicres-23-58]\]       Turkey-2013        Cohort         140      66         44.3                                 41.3                                    PC \[AF: 245±73 *vs.* SR: 264±94\]\
                                                                                                                                                                                       MPV \[AF: 9.7±0.9 *vs.* SR: 9.1±1\]

  Kahn \[[@b67-medscimonitbasicres-23-58]\]         Canada-1997        Case-control   75       72.7       100%                                 100%                                    PC \[AF: 253±82 *vs.* SR: 230±98\]

  Gustafsson \[[@b72-medscimonitbasicres-23-58]\]   Sweden-1990        Case-control   40       70         --                                   --                                      PC \[AF: 188±37 *vs.* SR: 148±8.7\]\
                                                                                                                                                                                       BTG \[AF: 40.1±5.8 *vs.* SR: 36.25±2.75\]\
                                                                                                                                                                                       PF4 \[AF: 5.77±2.05 *vs.* SR: 3.77±1.07\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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